Free Trial
NASDAQ:VRCA

Verrica Pharmaceuticals (VRCA) Stock Price, News & Analysis

Verrica Pharmaceuticals logo
$0.83 +0.12 (+17.45%)
Closing price 07/7/2025 04:00 PM Eastern
Extended Trading
$0.88 +0.05 (+6.14%)
As of 07:11 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Verrica Pharmaceuticals Stock (NASDAQ:VRCA)

Key Stats

Today's Range
$0.70
$0.84
50-Day Range
$0.41
$0.83
52-Week Range
$0.38
$8.98
Volume
675,960 shs
Average Volume
617,320 shs
Market Capitalization
$76.77 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.00
Consensus Rating
Hold

Company Overview

Verrica Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
72nd Percentile Overall Score

VRCA MarketRank™: 

Verrica Pharmaceuticals scored higher than 72% of companies evaluated by MarketBeat, and ranked 266th out of 913 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Verrica Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.20, and is based on 1 buy rating, 4 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Verrica Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.

  • Read more about Verrica Pharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for Verrica Pharmaceuticals are expected to grow in the coming year, from ($1.46) to ($0.74) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Verrica Pharmaceuticals is -0.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Verrica Pharmaceuticals is -0.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Read more about Verrica Pharmaceuticals' valuation and earnings.
  • Percentage of Shares Shorted

    6.98% of the float of Verrica Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Verrica Pharmaceuticals has a short interest ratio ("days to cover") of 9.2.
  • Change versus previous month

    Short interest in Verrica Pharmaceuticals has recently increased by 30.84%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Verrica Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Verrica Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    6.98% of the float of Verrica Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Verrica Pharmaceuticals has a short interest ratio ("days to cover") of 9.2.
  • Change versus previous month

    Short interest in Verrica Pharmaceuticals has recently increased by 30.84%, indicating that investor sentiment is decreasing significantly.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Verrica Pharmaceuticals this week, compared to 2 articles on an average week.
  • Search Interest

    2 people have searched for VRCA on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Verrica Pharmaceuticals insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    54.00% of the stock of Verrica Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    42.45% of the stock of Verrica Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Verrica Pharmaceuticals' insider trading history.
Receive VRCA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Verrica Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

VRCA Stock News Headlines

Elon’s BIGGEST warning yet?
Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… The "experts" said Elon was finished and Tesla was headed for bankruptcy. Now they're saying the same thing, but Jeff has uncovered Tesla's next breakthrough.
See More Headlines

VRCA Stock Analysis - Frequently Asked Questions

Verrica Pharmaceuticals' stock was trading at $0.70 at the beginning of the year. Since then, VRCA stock has increased by 18.6% and is now trading at $0.83.

Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) released its quarterly earnings data on Tuesday, May, 13th. The company reported ($0.10) EPS for the quarter, topping the consensus estimate of ($0.14) by $0.04. The firm earned $3.44 million during the quarter, compared to analyst estimates of $2.53 million.
Read the conference call transcript
.

Verrica Pharmaceuticals (VRCA) raised $75 million in an initial public offering on Friday, June 15th 2018. The company issued 5,000,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, Jefferies and Cowen acted as the underwriters for the IPO.

Shares of VRCA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Verrica Pharmaceuticals investors own include Meta Platforms (META), Paycom Software (PAYC), Walt Disney (DIS), uniQure (QURE), Marathon Oil (MRO), Centrus Energy (LEU) and Clean Energy Fuels (CLNE).

Company Calendar

Last Earnings
5/13/2025
Today
7/07/2025
Next Earnings (Estimated)
8/13/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - DRUGS
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:VRCA
Fax
N/A
Employees
40
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$8.00
High Stock Price Target
$12.00
Low Stock Price Target
$2.00
Potential Upside/Downside
+863.9%
Consensus Rating
Hold
Rating Score (0-4)
2.20
Research Coverage
5 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$76.58 million
Pretax Margin
-919.21%

Debt

Sales & Book Value

Annual Sales
$7.57 million
Price / Cash Flow
N/A
Book Value
($0.11) per share
Price / Book
-7.55

Miscellaneous

Free Float
42,546,000
Market Cap
$76.77 million
Optionable
Optionable
Beta
1.76
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.

Get This Free Report

This page (NASDAQ:VRCA) was last updated on 7/8/2025 by MarketBeat.com Staff
From Our Partners